Literature DB >> 35532224

Characterization of the Serpentine Adeno-Associated Virus (SAAV) Capsid Structure: Receptor Interactions and Antigenicity.

Mario Mietzsch1, Joshua A Hull1, Victoria E Makal1, Alberto Jimenez Ybargollin1, Jennifer C Yu1, Kedrick McKissock1, Antonette Bennett1, Judit Penzes1, Bridget Lins-Austin1, Qian Yu2, Paul Chipman1, Nilakshee Bhattacharya3, Duncan Sousa3, David Strugatsky4, Peter Tijssen2, Robert McKenna1, Mavis Agbandje-McKenna1.   

Abstract

Adeno-associated viruses (AAVs) are being developed as clinical gene therapy vectors. One issue undermining their broad use in the clinical setting is the high prevalence of circulating antibodies in the general population capable of neutralizing AAV vectors. Hence, there is a need for AAV vectors that can evade the preexisting immune response. One possible source of human naive vectors are AAVs that do not disseminate in the primate population, and one such example is serpentine AAV (SAAV). This study characterizes the structural and biophysical properties of the SAAV capsid and its receptor interactions and antigenicity. Single particle cryo-electron microscopy (cryo-EM) and thermal stability studies were conducted to characterize the SAAV capsid structure at pH 7.4, 6.0, 5.5, and 4.0, conditions experienced during cellular trafficking. Cell binding assays using Chinese hamster ovary (CHO) cell lines identified terminal sialic acid as the primary attachment receptor for SAAV similar to AAV1, 4, 5, and 6. The binding site of sialic acid to the SAAV capsid was mapped near the 2-fold axis toward the 2/5-fold wall, in a different location than AAV1, 4, 5, and 6. Towards determining the SAAV capsid antigenicity native immunodot blots showed that SAAV evades AAV serotype-specific mouse monoclonal antibodies. However, despite its reptilian origin, it was recognized by ~25% of 50 human sera tested, likely due to the presence of cross-reactive antibodies. These findings will inform future gene delivery applications using SAAV-based vectors and further aid the structural characterization and annotation of the repertoire of available AAV capsids. IMPORTANCE AAVs are widely studied therapeutic gene delivery vectors. However, preexisting antibodies and their detrimental effect on therapeutic efficacy are a primary challenge encountered during clinical trials. In order to circumvent preexisting neutralizing antibodies targeting mammalian AAV capsids, serpentine AAV (SAAV) was evaluated as a potential alternative to existing mammalian therapeutic vectors. The SAAV capsid was found to be thermostable at a wide range of environmental pH conditions, and its structure showed conservation of the core capsid topology but displays high structural variability on the surface. At the same time, it binds to a common receptor, sialic acid, that is also utilized by other AAVs already being utilized in gene therapy trials. Contrary to the initial hypothesis, SAAV capsids were recognized by one in four human sera tested, pointing to conserved amino acids around the 5-fold region as epitopes for cross-reacting antibodies.

Entities:  

Keywords:  AAV; adeno-associated virus; antibody; capsid; cryo-EM; gene therapy; human sera; parvovirus; receptor; sialic acid

Mesh:

Substances:

Year:  2022        PMID: 35532224      PMCID: PMC9175632          DOI: 10.1128/jvi.00335-22

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  86 in total

1.  Cloning of an avian adeno-associated virus (AAAV) and generation of recombinant AAAV particles.

Authors:  Ioannis Bossis; John A Chiorini
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

2.  Structure of adeno-associated virus serotype 8, a gene therapy vector.

Authors:  Hyun-Joo Nam; Michael Douglas Lane; Eric Padron; Brittney Gurda; Robert McKenna; Erik Kohlbrenner; George Aslanidi; Barry Byrne; Nicholas Muzyczka; Sergei Zolotukhin; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

3.  Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer.

Authors:  Nagesh Pulicherla; Shen Shen; Swati Yadav; Kari Debbink; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; Aravind Asokan
Journal:  Mol Ther       Date:  2011-03-01       Impact factor: 11.454

4.  Cryo-EM maps reveal five-fold channel structures and their modification by gatekeeper mutations in the parvovirus minute virus of mice (MVM) capsid.

Authors:  Suriyasri Subramanian; Lindsey J Organtini; Alec Grossman; Phillip P Domeier; Javier O Cifuente; Alexander M Makhov; James F Conway; Anthony D'Abramo; Susan F Cotmore; Peter Tattersall; Susan Hafenstein
Journal:  Virology       Date:  2017-07-24       Impact factor: 3.616

5.  Structural characterization of the dual glycan binding adeno-associated virus serotype 6.

Authors:  Robert Ng; Lakshmanan Govindasamy; Brittney L Gurda; Robert McKenna; Olga G Kozyreva; R Jude Samulski; Kristin N Parent; Timothy S Baker; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

6.  Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly.

Authors:  Joshua C Grieger; Stephen Snowdy; Richard J Samulski
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

7.  Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.

Authors:  C Summerford; R J Samulski
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

8.  PHENIX: a comprehensive Python-based system for macromolecular structure solution.

Authors:  Paul D Adams; Pavel V Afonine; Gábor Bunkóczi; Vincent B Chen; Ian W Davis; Nathaniel Echols; Jeffrey J Headd; Li-Wei Hung; Gary J Kapral; Ralf W Grosse-Kunstleve; Airlie J McCoy; Nigel W Moriarty; Robert Oeffner; Randy J Read; David C Richardson; Jane S Richardson; Thomas C Terwilliger; Peter H Zwart
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

Review 9.  Twenty-Five Years of Structural Parvovirology.

Authors:  Mario Mietzsch; Judit J Pénzes; Mavis Agbandje-McKenna
Journal:  Viruses       Date:  2019-04-20       Impact factor: 5.048

10.  Characterization of the GBoV1 Capsid and Its Antibody Interactions.

Authors:  Jennifer Chun Yu; Mario Mietzsch; Amriti Singh; Alberto Jimenez Ybargollin; Shweta Kailasan; Paul Chipman; Nilakshee Bhattacharya; Julia Fakhiri; Dirk Grimm; Amit Kapoor; Indrė Kučinskaitė-Kodzė; Aurelija Žvirblienė; Maria Söderlund-Venermo; Robert McKenna; Mavis Agbandje-McKenna
Journal:  Viruses       Date:  2021-02-20       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.